Atlas Trials

Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis

Clinical trial NCT06015100 · UNKNOWN

Trial details

NCT number
NCT06015100
Sponsor
Yan Xue
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Breast Cancer
Start date
2021-02-20
Primary completion
2023-08-31
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.